Section IV
31 – 40 of 7286
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Primary healthcare professionals’ attitudes toward patients with current or previous drug use
2024) In Scandinavian Journal of Primary Health Care(
- Contribution to journal › Article
-
Mark
Early findings in a randomised controlled trial on crosslinking protocols using isoosmolar and hypoosmolar riboflavin for the treatment of progressive keratoconus
(
- Contribution to journal › Article
-
Mark
Increasing plasma calprotectin (S100A8/A9) is associated with 12-month mortality and unfavourable functional outcome in critically ill COVID-19 patients
(
- Contribution to journal › Article
-
Mark
Impact of Magnetic Resonance Imaging Markers on the Diagnostic Performance of the International Parkinson and Movement Disorder Society Multiple System Atrophy Criteria
2024) In Movement Disorders(
- Contribution to journal › Article
-
Mark
Active forgetting in post-traumatic stress : Adaptive memory control
2024) In Nature Reviews Psychology(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Novel Bioimaging Techniques using Spectral Information for Monitoring Oxygen Saturation - Evaluated in Human Models of Skin Hypoperfusion
2024) In Lund University, Faculty of Medicine Doctoral Dissertation Series(
- Thesis › Doctoral thesis (compilation)
-
Mark
Protocolized reduction of non-resuscitation fluids versus usual care in septic shock patients (REDUSE) : a randomized multicentre feasibility trial
(
- Contribution to journal › Article
-
Mark
A Comparison of Brain-State Representations of Binary Neuroimaging Connectivity Data. Comment on Samantaray et al. Unique Brain Network Identification Number for Parkinson’s and Healthy Individuals Using Structural MRI. Brain Sci. 2023, 13, 1297
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
A comparative study of fatigue and processing speed in patients with multiple sclerosis treated with natalizumab or rituximab
(
- Contribution to journal › Article
-
Mark
COMBAT-MS : A Population-Based Observational Cohort Study Addressing the Benefit–Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab
2024) In Annals of Neurology(
- Contribution to journal › Article